Half-year report · Q2
2796.TEDINET S100V2NV
Period2024-06-01 → 2024-11-30
Filed2025-01-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥54.5bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥100m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥710m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥29m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥833m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥701m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥34m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥662m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥113m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥351m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥273m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥121m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥282m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥30.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥29.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥23.0bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥22.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.2bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥7.4bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.4bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.5bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.2bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥200m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥537m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥543m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-10.09 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-33.41 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.29 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.99 | 2023-06-01 → 2023-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.6% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥175m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥1m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥311m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥311m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥22m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥202m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥256m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥256m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥58m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥282m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥276m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥162m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥38m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥21m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥831m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥56m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥870m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥872m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 560
| Item | Context | Value | Unit |
|---|---|---|---|
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社ビックフィールド | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都杉並区南荻窪２丁目18―14 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社スズケン | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)愛知県名古屋市東区東片端町８ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)大野 小夜子 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都杉並区 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)ファーマライズ従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中野区中央１丁目38―１ | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)中北薬品株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)愛知県名古屋市中区丸の内３丁目11―９ | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)株式会社バイタルネット | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)宮城県仙台市青葉区大手町１―１ | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)大野 利美知 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都杉並区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)ヒグチ産業株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)大阪府東大阪市鴻池徳庵町１－６ | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)日医工株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)富山県富山市総曲輪１丁目６－２１ | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)エア・ウォーター株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区南船場２丁目１２－８号 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない 当社における標準となる株式 単元株式数100株 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)同上 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ファーマライホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都中野区中央１丁目38－１ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |